NCT03483246Active, not recruitingPhase 3
Impact of Fecal Microbiota Transplantation in Ulcerative Colitis
Impact of Fecal Microbiota Transplantation in Ulcerative Colitis: a Randomized, Sham Controlled Trial
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease. UC pathogenesis remains poorly understood but involves an inappropriate immune response toward an unbalanced gut microbiota (called dysbiosis) in predisposed hosts. The purpose of this study is to determine the effect of the fecal microbiota transplantation on UC.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 26 Feb 2018
- Start date
- 17 Sept 2018
- Primary completion date
- 16 Sept 2025
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Ulcerative colitis
- NCT number
- NCT03483246
- EU CT number
- 2024-511863-27-01
- EudraCT number
- 2017-003802-42
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 150
- From 17 Sept 2018 to the primary completion date, 16 Sept 2025
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.